Poly- and autoreactivity of HIV-1 bNAbs: implications for vaccine design

Joel Finney1 and Garnett Kelsoe1,2*

Abstract
A central puzzle in HIV-1 research is the inability of vaccination or even infection to reliably elicit humoral responses against broadly neutralizing epitopes in the HIV-1 envelope protein. In infected individuals, broadly neutralizing antibodies (bNAbs) do arise in a substantial minority, but only after 2 or more years of chronic infection. All known bNAbs possess at least one of three traits: a high frequency of somatic hypermutation, a long third complementarity determining region in the antibody heavy chain (HCDR3), or significant poly- or autoreactivity. Collectively, these observations suggest a plausible explanation for the rarity of many types of bNAbs: namely, that their generation is blocked by immunological tolerance or immune response checkpoints, thereby mandating that B cells take a tortuous path of somatic evolution over several years to achieve broadly neutralizing activity. In this brief review, we discuss the evidence for this tolerance hypothesis, its implications for HIV-1 vaccine design, and potential ways to access normally forbidden compartments of the antibody repertoire by modulating or circumventing tolerance controls.

Background
A principal aim of HIV-1 vaccine research is to elicit routinely broadly neutralizing antibodies (bNAbs), which target conserved, functionally important determinants on the HIV-1 envelope (Env) and consequently neutralize across viral clades [1]. However, bNAbs are difficult to elicit, arising in no more than 50% of HIV-1 patients, and only after 2 or more years of chronic infection [1–4]. Moreover, while vaccination with Env-derived antigens can initiate some bNAb lineages, substantive maturation of neutralization breadth and potency toward native viral isolates has not yet been achieved [5–9]. Several non-mutually exclusive hypotheses have been proposed to explain why generation of HIV-1 bNAbs is so challenging [10–12]. In this short review, we focus on the tolerance hypothesis [13], which posits that due to viral molecular mimicry of host structures, the B cells most fit to respond to broadly conserved, neutralizing epitopes are poly- or autoreactive, and have been removed from the repertoire by immunological tolerance controls [13–15].

In the most general terms, polyreactive Abs are those that promiscuously bind apparently unrelated self- and/or foreign-antigens, while autoreactive Abs specifically bind one or few self-epitopes. Poly- and autoreactivity in Abs are empirically defined. One method defines autoreactivity as the ability of an Ab to bind any self-antigen, and defines polyreactivity as the ability to bind (in ELISA) two or more antigens from a set list that generally includes single-stranded DNA, double-stranded DNA (dsDNA), insulin, lipopolysaccharide, and keyhole limpet hemocyanin [16, 17]. Another method, established by our laboratory, determines poly- and autoreactivity by applying the Ab of interest together with a non-polyreactive control Ab to a microarray that displays >9400 human proteins [18, 19]. Ab binding strength to each protein target is measured as fluorescence intensity, and if the averaged binding intensity over all arrayed proteins (i.e., mean fluorescence intensity; MFI) of the test Ab is >twofold greater than the MFI of the control Ab, then the experimental Ab is considered polyreactive (Fig. 1a) [19]. Non-polyreactive test Abs that bind a self-protein in the array with >500-fold higher avidity than...
the control Ab are considered autoreactive (Fig. 1b) [19]. Notably, some polyreactive Abs also bind autoantigens with >500-fold higher avidity than the control. However, for simplicity, we reserve the term autoreactive to describe non-polyreactive Abs, since substantial cumulative autoreactivity is already implied for Abs labeled polyreactive [19].

That many B-cell receptors (BCRs) recognize self-antigens is an inevitable by-product of the extraordinary diversity of BCRs generated during B-cell development. Indeed, ~75% of newly assembled human BCRs react with self-antigens [16]. This prevalent autoreactivity is potentially dangerous to the host, as evidenced by the generation of pathologic autoantibodies in many autoimmune diseases [20, 21]. Thus, mechanisms of immunological tolerance eliminate or silence autoreactive B cells at discrete checkpoints during B-cell development. At each checkpoint, autoreactive B cells are purged by clonal deletion (i.e., apoptosis) [22–24]; modified by receptor editing, in which continued V(D)J recombination alters BCR specificity [25, 26]; or rendered anergic (i.e., highly resistant to BCR stimulation and plasmacytic...
differentiation) [27, 28]. In consequence, the frequency of autoreactive B cells is reduced from 75% in the early immature B-cell stage to ~20% among mature B cells in healthy humans [16]. Concomitantly, there are dramatic reductions in the frequencies of polyreactive BCRs as well as those with a long third complementarity determining region in the Ab heavy chain (HCDR3) [16, 29, 30], suggesting that these properties are linked to autoreactivity and are efficiently counter-selected by immune tolerance controls. Finally, autoreactive BCRs also may be generated by V(D)J somatic hypermutation (SHM) in germinal center (GC) B cells [31]. These newly autoreactive GC B cells may be culled or silenced by apoptosis and other means [31–37], or else may be “redeemed” from negative selection by ongoing SHM that abolishes autospecificity [38–41]. Thus, healthy individuals constrain the B-cell repertoire to avoid generating potentially pathogenic self-reactive humoral responses.

The necessary evil of immunological tolerance is that it creates “holes” in the BCR repertoire. By having vulnerable epitopes mimic the molecular structures of host antigens, pathogens can exploit these holes and evade humoral responses [42]. In the following sections, we discuss (1) the evidence of molecular mimicry by HIV-1 broadly neutralizing epitopes, (2) the role of immune tolerance controls in suppressing the generation of bNAbs, and (3) possible strategies for accessing the forbidden BCR repertoire to achieve broad protection during HIV-1 vaccination.

Immune tolerance blocks bNAb generation

HIV-1 bNAbs each exhibit at least one of these uncommon traits: poly- or autoreactivity, a long HCDR3, and/or extraordinary frequencies of V(D)J mutations. It is these features that suggest the hypothesis that immunological tolerance disfavours bNAb generation [13, 14]. Poly- or autoreactive B-cell antigen receptors (BCRs) are eliminated from the primary repertoire at central and peripheral tolerance checkpoints [16, 43, 44], and there is evidence that BCRs with long HCDR3s—which themselves are frequently poly- or autoreactive—are also filtered from the repertoire during B-cell development [29, 30]. While the impetus for extensive somatic hypermutation in bNAbs is unclear, it is plausible that in the absence of competition, B cells with initially poor binding to broadly neutralizing epitopes undergo tortuous and prolonged affinity maturation pathways until broad neutralization is achieved.

Initial evidence for the tolerance hypothesis arose from the discovery that some bNAbs, including 2F5 and 4E10, cross-react with self-lipids (e.g., cardiolipin) and various self-protein antigens in vitro [14]. The next test of the hypothesis was to determine whether bNAb autoreactivity is physiologically relevant for B-cell development, i.e., whether tolerance mechanisms counterselect developing B cells expressing mature bNAbs or their precursors. This was directly tested in knockin (KI) mice expressing the rearranged heavy- and light-chain (HC + LC) variable regions of mature bNAbs or their unmutated germline (gl) precursors. In support of the tolerance hypothesis, mice expressing the HC + LC of 2F5, gl2F5, 4E10, gl3BNC60, or HC of 2F5 or gl3BNC60 [5, 45–50] exhibited one or more traits—including marked clonal deletion of developing B cells, extensive BCR editing, and anergy in peripheral B cells—that define the tolerance controls observed in mice that express transgenic autoreactive BCRs [22, 23, 25, 26, 28, 51, 52]. Thus, the autoreactivity of bNAbs and their germline precursors is, in many cases, sufficient to proscribe normal development of B cells bearing these BCRs.

Knowing that immunological tolerance mechanisms often prohibit the development of B cells expressing mature or precursor bNAbs, our lab set out to isolate and identify the autoantigens recognized by bNAbs. In early studies, we used 2F5 and 4E10 to immunoprecipitate antigens from human cell lysates, and then identified the precipitated targets by peptide mass fingerprinting, followed by stringent immunoassays to filter the candidate list [18]. In this way, kynureninase (KYNU) was identified as the primary self-antigen bound by mature and gl2F5 bNAbs, whereas splicing factor 3b subunit 3 (SF3B3) was the principal target of 4E10 [18]. Strikingly, the complete 2F5 linear epitope (ELDKWA) is shared by HIV-1 Env and the known KYNU orthologs in most mammals, with the notable exception of opossums, which carry a point mutation in KYNU that abolishes 2F5 binding [18]. Accordingly, immunization of opossums resulted in ELDKWA-specific serum Ab titers that were ≥100-fold higher than in immunized mice; however, immunization did not generate opossum antibodies to the adjacent 4E10 epitope, consistent with the high degree of conservation between human and opossum SF3B3 [18]. That opposums can generate 2F5-like antibodies is not due to intrinsically longer HCDR3 segments in opossum antibodies, since the average HCDR3 length is equivalent (12–13 amino acids) in opossum and mouse BCRs [53, 54]. Rather, mice also have in their pre-tolerance BCR repertoire the latent capacity to respond to the ELDKWA epitope, and this specificity is eliminated by immunological tolerance. This was demonstrated in animals reconstituted with B cells that had bypassed central tolerance via an in vitro culture system [55]. After immunization with MPER peptide, reconstituted mice formed robust GC responses, whereas control animals did not [55]. Moreover, after secondary immunization, the MPER-specific serum IgG response was 12-fold higher in reconstituted
mice than in controls [55]. Recently, we have determined that BCR specificity for KYNU and Env are almost perfectly correlated in 2F5 HC+ LC KI mice: B cells that bind both KYNU and Env exist only prior to the first tolerance checkpoint or in a fraction of the peripheral IgM+ IgD+ anergic B-cell pool, whereas no post-tolerance checkpoint mature B cell reacts with either KYNU or Env (Finney et al., manuscript in preparation). These data support the hypothesis that at least some broadly neutralizing viral epitopes avoid the immune response by mimicking host antigens and thereby hiding in “holes” created in the B-cell repertoire by immunological tolerance controls.

To determine whether poly/autoreactivity is linked with broadly neutralizing activity, rather than being merely a product of chronic infection (e.g., persistent inflammation, prolonged Ag exposure, etc.) [56–58], we used microarrays displaying > 9400 human proteins to screen panels of bNAbs and non-broadly neutralizing Abs (nNAbs, including non-neutralizing and autologous neutralizing Abs) alongside a non-polyreactive control Ab [18, 19]. We defined polyreactive Abs as those whose averaged array binding was > twofold greater than the control Ab, whereas autoreactive Abs were non-polyreactive Abs that bound at least one self-protein with > 500-fold higher avidity than the control Ab (Fig. 1) [19]. Using these criteria, we found that ~ 20% (2/9) of nNAbs were poly- or autoreactive [19], which is indistinguishable from the frequency of poly- and autoreactive B cells found among mature peripheral B cells in healthy humans [16]. In contrast, ~ 60% (13/22) of bNAbs were poly- or autoreactive, including ≥ 1 polyreactive bNAb in each of four major bNAb classes: CD4 binding-site, membrane-proximal external region (MPER), variable loops 1 and 2, and variable loop-associated glycan [19]. Importantly, bNAbs were also significantly enriched for poly/autoreactivity compared to the nNAbs isolated from infected patients (i.e., excluding nNAbs arising from vaccination) [19]. Thus, bNAb poly/autoreactivity is not a product of the infection milieu. Moreover, while the average frequency of Vh somatic mutations was substantially higher in bNAbs (20.5%) than in nNAbs (10%), SHM was not correlated with poly- or autoreactivity [19]. Likewise, whereas the average HCDR3 length in bNAbs (19.4 amino acids) was substantially longer than in nNAbs (14.7 amino acids), HCDR3 length did not correlate with poly- or autoreactivity. These data support that poly/autoreactivity is intrinsically linked to broadly neutralizing activity.

Notably, ~ 40% of bNAbs were neither poly- nor autoreactive when assessed for self-protein binding, raising the question of why they remain difficult to elicit. The protein array likely underestimates poly/autoreactivity, since some bNAbs engage non-protein self-molecules, e.g., PGT121 avidly binds self-glycans, even in the absence of protein determinants [19, 59–61]. Additionally, there are other proposed barriers to bNAb generation, including the sparsity of Env spikes on virions [62–64], conformational masking of broadly neutralizing epitopes [65, 66], immunological dominance of non-broadly neutralizing epitopes [1], and the requirement of some bNAb lineages for specific V-, D-, or J-gene allelic variants [67].

Implications for vaccine design

In light of the role that immunological tolerance plays in barring the generation of many bNAbs, there are at least two potential strategies for a universal HIV-1 vaccine. One tactic is to work within the constraints of tolerance controls to elicit only those types of bNAbs not proscribed by immune tolerance. The second approach would be to design an immunization regimen that modulates or “breaks” tolerance to gain access to bNAb precursors in the forbidden repertoire. The former strategy, unlike the latter, carries no additional risk of developing autoimmune disease, and therefore is likely to face fewer barriers to regulatory approval and wide use. However, the potential shortcoming of this method is that it must achieve neutralization by targeting only a subset of vulnerable epitopes. In consequence, bNAbs would have to arise from an even smaller pool of already rare precursors. This limitation could further confound vaccination efforts, since precursor cell frequency may be an important determinant of B-cell competitiveness in anti-Env humoral responses [68, 69], and variability in the human BCR repertoire might preclude the generation of certain bNAb lineages in individuals lacking the required V-, D-, or J-gene allelic variants [12, 67]. However, these remain open questions and are potentially surmountable obstacles.

The second strategy—to break tolerance—has been recently attempted, with some success. 2F5 KI mice were repeatedly immunized with MPER peptide-conjugated liposomes (engineered to mimic the MPER epitopes present on virions) and TLR agonists [5, 70]. In 2F5 HC+ LC KI mice, this method successfully overcame B-cell anergy to activate and expand populations of MPER-binding B cells, and also elicited substantial serum titers of MPER-specific neutralizing IgG [70]. Similarly, in g2F5 KI mice, MPER-liposome vaccination induced selectivity proliferation of MPER-specific B cells; however, it failed to induce class-switch recombination and somatic hypermutation, and generated poor serum titers of anti-MPER IgM [5]. Likewise, in gL3BNC60 HC+ LC KI mice, only highly multimerized immunogen (rather than trimeric immunogen) could reliably elicit serum antibody responses specific for the CD4 binding site [46]. However, activated
widely used antimalarial drug, to inhibit endosome acidification and relaxion of tolerance controls could result in autoimmunity in conjunction with vaccination, since extended these treatments would have to be transient and carefully managed to prevent the generation of bNAb lineages, since the B cells most fit to respond functionally important viral structures as various host proteins. In consequence, traditional vaccination strategies do not appear to be suitable for eliciting many bNAb lineages, since the B cells most fit to respond to these pathogens whose vulnerable epitopes structurally mimic self-antigens. From structural/biochemical studies of bNAbs and the generation of bNAb-knockin mice, it is now clear that HIV-1 is such a pathogen, disguising conserved, epitopes does not a priori disqualify this immunization strategy. Therefore, while any vaccine regimen designed to generate autoreactive bNAbs would have to be evaluated with extra rigor to assure safety, host mimicry by many bNAb epitopes does not perform obvious side effects [74].

Concluding remarks

B-cell tolerance controls are necessary to prevent the generation of self-antibodies and autoimmune disease. However, tolerance creates empty spaces in the Ab repertoire and these “holes” can be exploited by pathogens whose vulnerable epitopes structurally mimic self-antigens. From structural/biochemical studies of bNAbs and the generation of bNAb-knockin mice, it is now clear that HIV-1 is such a pathogen, disguising conserved, functionally important viral structures as various host proteins. In consequence, traditional vaccination strategies do not appear to be suitable for eliciting many bNAb lineages, since the B cells most fit to respond have been eliminated or silenced during their development, maturation, or antigen-driven expansion. These obstacles to effective HIV-1 vaccination, while serious, are not insurmountable. Recent evidence demonstrates that tolerance controls can be relaxed or broken to gain access to this forbidden Ab repertoire, without inducing
autoimmune disease. Additionally, subtle structural differences between self-antigens and the foreign molecules that mimic them might permit initially autoreactive, physiologically silenced BCRs to be permitted by V(D)J mutations that impair self-reactivity in GCs. Future studies in this field will likely focus on these aspects, particularly with regard to techniques for transiently modulating immunological tolerance in conjunction with vaccination, which have the potential to provide broad, durable protection.

**Abbreviations**
Ab: antibody; BCR: B-cell receptor; bNAb: broadly neutralizing antibody; DEL: duck egg lysozyme; dsDNA: double-stranded DNA; Env: envelope protein; GC: germinal center; gl: germline; HC: heavy chain; HCDR3: heavy chain complementary-determining region; HEL: triply mutated hen egg lysozyme; Kt: knockin; KNYU: kynureninase; LC: light chain; MFI: mean fluorescence intensity; MPER: membrane-proximal external region; nNAb: non-broadly neutralizing antibody; SF3B3: splicing factor 3b subunit 3; SHM: somatic hypermutation.

**Authors’ contributions**
JF and GK wrote the manuscript. Both authors read and approved the final manuscript.

**Author details**
1 Department of Immunology, Duke University, DUMC 3010, Durham, NC 27710, USA. 2 Human Vaccine Institute, Duke University, Durham, NC 27710, USA.

**Acknowledgements**
Not applicable.

**Competing interests**
The authors declare that they have no competing interests.

**Availability of data and materials**
Not applicable.

**Consent for publication**
Not applicable.

**Ethics approval and consent to participate**
Not applicable.

**Funding**
This work was supported in part by NIH awards AI089618 (to G.K.).

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Received: 31 May 2018   Accepted: 23 July 2018**

**Published online: 28 July 2018**

**References**
1. Mascola JR, Haynes BF. HIV-1 neutralizing antibodies: understanding nature’s pathways. Immunol Rev. 2013;254:225–44.
2. Gray ES, Madiga MC, Hermansus T, Moore PL, Wibmer CK, Tumba NL, Werner L, Misiana K, Sibeko S, Williamson C, et al. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol. 2011;85:4828–40.
3. Mikell I, Sather DN, Kalams SA, Atfield M, Alter G, Stamatakis L. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog. 2011;7:e1001251.
4. Haber P, Seaman MS, Bailer RT, Mascola JR, Montefiori DC, Korber BT. Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS. 2014;28:163–9.
5. Zhang R, Verkoczy L, Wiehe K, Munir Alam S, Nicely NI, Santra S, Bradley T, Pemble CW, Zhang J, Gao F, et al. Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineages. Sci Transl Med. 2016;8:336ra362.
6. Briney B, Sok D, Jardine GD, Kulp DW, Skog P, Menis S, Jacak R, Kalyuzhnii O, de Val N, Sesterhenn F, et al. Tailored immunogens direct affinity maturation toward HIV neutralizing antibodies. Cell. 2016;166:1459–1470.e1411.
7. Escolano A, Steichen JM, Dosenovic P, Kulp DW, Golijanin J, Sok D, Freund NT, Gritlin AD, Oliveira T, Araki T, et al. Sequential immunization elicits broadly neutralizing anti-HIV-1 antibodies in Ig knockin mice. Cell. 2016;166:1445–1458.e1412.
8. Xu K, Acharya P, Kong R, Cheng C, Chuang GY, Liu K, Louder MK, O’Dell S, Rawi R, Sastry M, et al. Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. Nat Med. 2018;24:857–67.
9. Dubrovskaia V, Guenaga J, de Val N, Wilson R, Feng Y, Movseyan A, Karlsson Hedestam GB, Ward AB, Wyatt RT. Targeted N-glycan deletion at the receptor-binding site retains Env HIV NFL trimer integrity and accelerates the elicited antibody response. PLoS Pathog. 2017;13:e1006614.
10. Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, Moore JP, Nabel GJ, Sodroski J, Wilson IA, Wyatt RT. HIV vaccine design and the neutralizing antibody problem. Nat Immunol. 2004;5:233–6.
11. Kwong PD, Mascola JR, Nabel GJ. Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. Cold Spring Harb Perspect Biol. 2012;1:14.
12. Haynes BF, Kelsoe G, Harrison SC, Kepler TB. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol. 2012;30:423–33.
13. Haynes BF, Moody MA, Verkoczy L, Kelsoe G, Alam SM. Antibody polyclonality and neutralization of HIV-1: a hypothesis. Hum Antibodies. 2005;14:59–67.
14. Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, Kunert R, Robinson J, Sceare RM, Plonk K, Staats HF, et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science. 2005;308:1906–8.
15. Kelsoe G, Haynes BF. Host controls of HIV broadly neutralizing antibody development. Immunol Rev. 2017;275:79–88.
16. Wardemann H, Yurasov S, Schafer A, Young JW, Meffre E, Nussenzwerg MC. Predominant autoantibody production by early human B cell precursors. Science. 2003;301:1374–7.
17. Mouquet H, Scheid JF, Zoller MJ, Krogsgaard M, Ott RG, Shukair S, Artymovych MN, Pietzsch J, Connors M, Pereyra F, et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature. 2010;467:591–5.
18. Yang G, Holl TM, Liu Y, Li Y, Lu X, Nicely NI, Kepler TB, Alam SM, Liao HX, Cain DW, et al. Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies. J Exp Med. 2013;210:241–56.
19. Liu M, Yang G, Wiehe K, Nicely NI, Vandergrift NA, Rountree W, Bonsignori M, Alam SM, Gao J, Haynes BF, Kelsoe G. Polyreactivity and autoreactivity among HIV-1 antibodies. J Virol. 2015;89:794–98.
20. Rowley MJ, Whittingham SF. The role of pathogenic autoantibodies in autoimmunity. Antibodies. 2015;4:314–53.
21. Suarmond J, Diamond B. Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity. J Clin Investig. 2015;125:2194–202.
22. Nermazee DA, Burki K. Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature. 1989;337:562–6.
23. Hartley SB, Crossbie J, Brink R, Kantor AB, Basten A, Goodnow CC. Elimination from peripheral lymphoid tissues of self-reactive B cell precursors. Science. 2003;301:1374–7.
24. Erikson J, Radic MZ, Camper SA, Hardy RR, Carmack C, Weigert M. Expression of anti-DNA immunoglobulin transgenes in non-autoimmune mice. Nature. 1991;349:331–4.
25. Gay D, Saunders T, Camper S, Weigert M. Receptor editing: an approach by autoreactive B cells to escape tolerance. J Exp Med. 1993;177:999–1008.

26. Tiegs SL, Russell DM, Nemazee D. Receptor editing in self-reactive bone marrow B cells. J Exp Med. 1993;177:1009–20.

27. Nossal GJ, Pilk B. Clonal anergy: persistence in tolerant mice of antigen-binding B lymphocytes incapable of responding to antigen or mitogen. Proc Natl Acad Sci USA. 1980;77:1602–6.

28. Goodnow CC, Crosbie J, Jorgensen H, Brink RA, Basten A. Induction of self-tolerance in mature peripheral B lymphocytes. Nature. 1982;303:385–91.

29. Larimore K, McCormick MW, Robins HS, Greenberg PD. Shaping of human germline IgH repertoires revealed by deep sequencing. J Immunol. 2012;189:3230–1.

30. Meffre E, Milli M, Blanco-Betancourt C, Antunes H, Nussenzweig MC, Schiff C. Immunoglobulin heavy chain expression shapes the B cell receptor repertoire in human B cell development. J Clin Investig. 2001;108:789–96.

31. DeFranco AL. Germinal centers and autoimmune disease in humans and mice. Immunity Cell Biol. 2016;94:918–24.

32. Chan TD, Wood K, Hermes JR, Chan TD, Jackson J, Goodnow CC. Clonal redemption of autoantibodies in transgenic mice. Nat Commun. 2016;7:10618.

33. Han S, Zheng B, Dal Porto J, Kelsoe G. In situ studies of the primary antibody repertoire in healthy human B cells. Proc Natl Acad Sci USA. 2015;112:1505–10.

34. Burnett DL, Langley DB, Schofield P, Hermes JR, Chan TD, Jackson J, Oliveira TY, Wang Q, Escolano A, et al. The microanatomic segregation of selection by apoptosis in the germinal center. Science. 2013;341:378–82.

35. Pulendran B, Kannourakis G, Smith KG, Nossal GJ. Soluble antigen can impede affinity maturation and the germinal center reaction but enhance extracellular immunoglobulin production. J Immunol. 1995;155:1141–50.

36. Wong EB, Soni C, Chan AT, Demeure PP, Abraham T, Limaye N, Khan TN, Ali MJ, Chodisetti SB, et al. The microanatomic segregation of selection by apoptosis in the germinal center. Science. 2013;341:378–82.

37. Wang X, Sharp AR, Miller RD. Early postnatal B cell ontogeny and antibody repertoire maturation in the opossum, Monodelphis domestica. PLoS ONE. 2012:e45931.
67. Alam SM, Liao HX, Dennison SM, Jaeger F, Parks R, Anasti K, Foulger A, Donathan M, Lucas J, Verkoczy L, et al. Differential reactivity of germline allelic variants of a broadly neutralizing HIV-1 antibody to a gp41 fusion intermediate conformation. J Virol. 2011;85:11725–31.
68. Abbott RK, Lee JH, Menis S, Skog P, Rossi M, Ota T, Kulp DW, Bhullar D, Kalyuzhniy O, Havenar-Daughton C, et al. Precursor frequency and affinity determine B cell competitive fitness in germinal centers, tested with germline-targeting HIV vaccine immunogens. Immunity. 2018;48(133–146):e136.
69. Dosenovic P, Kara EE, Pettersson AK, McGuire AT, Gray M, Hartweger H, Thientosapol ES, Stamatos A, Nussenzweig MC. Anti-HIV-1 B cell responses are dependent on B cell precursor frequency and antigen-binding affinity. Proc Natl Acad Sci USA. 2018;115:4743–8.
70. Verkoczy L, Chen Y, Zhang J, Bouton-Verville H, Newman A, Lockwood B, Scearce RM, Montefiori DC, Dennison SM, Xia SM, et al. Induction of HIV-1 broad neutralizing antibodies in 2F5 knock-in mice: selection against membrane proximal external region-associated autoreactivity limits T-dependent responses. J Immunol. 2013;191:2538–50.
71. Kuraoka M, Snowden PB, Nojima T, Verkoczy L, Haynes BF, Kitamura D, Kelsoe G. BCR and endosomal TLR signals synergize to increase AID expression and establish central B cell tolerance. Cell Rep. 2017;18:1627–35.
72. Kitaura Y, Jang IK, Wang Y, Han YC, Inazu T, Cadera EJ, Schissel M, Hardy RR, Gu H. Control of the B cell-intrinsic tolerance programs by ubiquitin ligases Cbl and Cbl-b. Immunity. 2007;26:567–78.
73. Vcelar B, Stiegler G, Wolf HM, Muntean W, Leschnik B, Mehandru S, Markowitz M, Armbruster C, Kunert R, Eibl MI, Katinger H. Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2FS and retrospective analysis of clinical safety data. AIDS. 2007;21:2161–70.
74. Bradley T, Yang G, Ilkayeva O, Holl TM, Zhang R, Zhang J, Santra S, Fox CB, Reed SG, Parks R, et al. HIV-1 envelope mimicry of host enzyme kynureninase does not disrupt tryptophan metabolism. J Immunol. 2016;197:4665–73.